COVID-19: US ACTIV Study Expands To Include Three Repurposed Drugs
More Products May Be Added To Trial Platform
Efforts to find new uses for old drugs in COVID-19 patients are gathering pace.
You may also be interested in...
Coronavirus Notebook: Egypt Boosts Vaccine Supply, Fenofibrate Shows ‘Astounding’ Results In Treating COVID-19
The European Medicines Agency has OKd more production sites for the manufacture of vaccines destined for the EU, the US and Australia have warned against taking ivermectin to protect against SARS-CoV-2 infection, and Italy has dismissed some ‘fake news’ about vaccine approvals.
The DARPin candidate will not gain emergency approval before early 2022, but its likely ability to sustain efficacy regardless of SARS-CoV-2 mutations could be valuable as new variants emerge.
NIH public-private partnership with FDA, CDC, BARDA and 16 biopharma companies to rank most promising therapeutics and vaccines to advance into clinical trials; candidates expected to be tested simultaneously under master protocol.